+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
CoMentis Inc - logo

CoMentis specializes in the development of small-molecule drugs to treat neurovascular diseases with a focus on Alzheimer's disease and schizophrenia. They cover the research and development spectrum from initial drug design through manufacturing and clinical trials. The company, with headquarters in South San Francisco, was formed by the merger of Zapaq, Inc. and Athenagen, Inc. in 2006. It is also working on nicotinic acetylcholine receptor modulators for the treatment of cognitive disorders.

Alzheimer's Disease Market (2nd edition) by Type of Treatment (Symptomatic and Disease Modifying), Symptomatic Indications (Dementia, Insomnia and Other Psychological Symptoms) and Geography (North America, Europe and Asia-Pacific), 2021-2030 - Product Thumbnail Image

Alzheimer's Disease Market (2nd edition) by Type of Treatment (Symptomatic and Disease Modifying), Symptomatic Indications (Dementia, Insomnia and Other Psychological Symptoms) and Geography (North America, Europe and Asia-Pacific), 2021-2030

  • Report
  • September 2021
  • 150 Pages
  • Global
From
Alzheimer's Disease Treatment Global Market Report 2024 - Product Thumbnail Image

Alzheimer's Disease Treatment Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Beta Secretase Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Beta Secretase Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Endotoxemia Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Endotoxemia Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • May 2023
  • 98 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator